IGMM Translation and Commercialisation Board (TCB)
Driving translation of IGMM science.
The IGMM TCB is responsible for the development, implementation and monitoring of the strategy for efficient translation of IGMM science and, where opportunities arise, to develop and commercialise innovative technologies to support future impact in medicine. We are comprised of IGMM researchers with diverse clinical, drug and biologics discovery and development expertise.
Enquiries relating to IGMM translation, partnerships and commercialisation should be addressed to:
Andrea Taylor, Business Development Manager, Edinburgh Innovations
Cell free DNA approaches
15 years' experience of translational research in the field of cystic fibrosis gene therapy
Senior member of the UK CF Gene Therapy Consortium's strategy group
Leadership of Phase IIb clinical trial of nonviral gene therapy for cystic fibrosis
Development of lentiviral gene therapy for cystic fibrosis in preparation for a Phase I nasal trial within the next 2-3 years